Menke Andy, Casagrande Sarah, Cowie Catherine C
Social & Scientific Systems, Inc, 8757 Georgia Avenue, 12th Floor, Silver Spring, MD 20910, USA.
National Institute of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Blvd, Rm 691, MSC 5460, Bethesda, MD 20892, USA.
BMC Endocr Disord. 2015 Sep 29;15:52. doi: 10.1186/s12902-015-0050-1.
Studies investigating the association between telomere length and diabetes have been inconsistent, and there are few data available investigating the associations of telomere length with diabetes duration and control. We evaluated the relationship of leukocyte telomere length with diabetes, and the relationship of leukocyte telomere length with diabetes duration and poor glucose control among people with diabetes.
We used data from the 1999-2002 National Health and Nutrition Examination Survey, a representative sample of the US civilian non-institutionalized population. In 3921 participants, leukocyte telomere length was measured and diabetes status was determined based on a previous diagnosis, hemoglobin A1c ≥ 6.5 %, or fasting glucose ≥ 126 mg/dL.
The odds ratios (95 % confidence intervals) of diabetes associated with the first, second, and third quartile of leukocyte telomere length, compared to the highest quartile, was 2.09 (1.46-2.98), 1.74 (1.30-2.31), and 1.08 (0.76-1.54), respectively (p-trend < 0.01), in unadjusted models and 0.74 (0.48-1.14), 0.91 (0.61-1.34), and 0.87 (0.59-1.29), respectively (p-trend = 0.20), in multivariable adjusted models. Among participants with diabetes, unadjusted and adjusted leukocyte telomere length was not associated with diabetes duration or glucose control based on an hemoglobin A1c < 7 or < 8 % (all p > 0.05).
In this study of the US general population, leukocyte telomere length was not associated with diabetes status, diabetes duration, or diabetes control.
关于端粒长度与糖尿病之间关联的研究结果并不一致,而且几乎没有数据可用于研究端粒长度与糖尿病病程及控制情况之间的关联。我们评估了白细胞端粒长度与糖尿病的关系,以及糖尿病患者中白细胞端粒长度与糖尿病病程及血糖控制不佳之间的关系。
我们使用了1999 - 2002年美国国家健康与营养检查调查的数据,这是美国非机构化平民人口的代表性样本。在3921名参与者中,测量了白细胞端粒长度,并根据既往诊断、糖化血红蛋白A1c≥6.5%或空腹血糖≥126mg/dL确定糖尿病状态。
在未调整模型中,与白细胞端粒长度最高四分位数相比,糖尿病与白细胞端粒长度第一、第二和第三四分位数相关联的优势比(95%置信区间)分别为2.09(1.46 - 2.98)、1.74(1.30 - 2.31)和1.08(0.76 - 1.54)(p趋势<0.01);在多变量调整模型中,分别为0.74(0.48 - 1.14)、0.91(0.61 - 1.34)和0.87(0.59 - 1.29)(p趋势 = 0.20)。在糖尿病患者中,如果糖化血红蛋白<7%或<8%,未调整和调整后的白细胞端粒长度与糖尿病病程或血糖控制均无关联(所有p>0.05)。
在这项针对美国普通人群的研究中,白细胞端粒长度与糖尿病状态、糖尿病病程或糖尿病控制均无关联。